Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
CVAC 
CureVac NV (CVAC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/11/2025: CVAC (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.39
1 Year Target Price $5.39
| 2 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 82.27% | Avg. Invested days 60 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 12/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.15B USD | Price to earnings Ratio 7.74 | 1Y Target Price 5.39 |
Price to earnings Ratio 7.74 | 1Y Target Price 5.39 | ||
Volume (30-day avg) 6 | Beta 1.77 | 52 Weeks Range 2.48 - 5.72 | Updated Date 12/11/2025 |
52 Weeks Range 2.48 - 5.72 | Updated Date 12/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.66 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-24 | When - | Estimate -0.15 | Actual -0.07 |
Profitability
Profit Margin 182.11% | Operating Margin (TTM) 573.04% |
Management Effectiveness
Return on Assets (TTM) 23.77% | Return on Equity (TTM) 40.22% |
Valuation
Trailing PE 7.74 | Forward PE 5.24 | Enterprise Value 705096433 | Price to Sales(TTM) 16.27 |
Enterprise Value 705096433 | Price to Sales(TTM) 16.27 | ||
Enterprise Value to Revenue 8.57 | Enterprise Value to EBITDA 3.35 | Shares Outstanding 225172749 | Shares Floating 114482951 |
Shares Outstanding 225172749 | Shares Floating 114482951 | ||
Percent Insiders 50 | Percent Institutions 10.42 |
Upturn AI SWOT
CureVac NV
Company Overview
History and Background
CureVac NV is a biopharmaceutical company founded in 2000 in Tu00fcbingen, Germany. It is a pioneer in messenger RNA (mRNA) technology. Key milestones include the development of its proprietary RNActiveu00ae platform, significant advancements in mRNA vaccine development, including a COVID-19 vaccine candidate, and its initial public offering (IPO) on the Nasdaq in 2020. The company has evolved to focus on developing a pipeline of mRNA-based therapeutics for various indications.
Core Business Areas
- mRNA Therapeutics: CureVac focuses on developing mRNA-based vaccines and therapeutics. Its platform enables the body's own cells to produce antigens or therapeutic proteins, triggering immune responses or treating diseases. This includes prophylactic vaccines and cancer immunotherapies.
- Prophylactic Vaccines: Development of vaccines against infectious diseases, leveraging mRNA technology for rapid response and potential for broad applicability.
- Oncology: Exploration of mRNA-based cancer immunotherapies, aiming to stimulate the immune system to recognize and attack tumor cells.
Leadership and Structure
CureVac NV is led by a management board and overseen by a supervisory board. Key leadership roles include the Chief Executive Officer (CEO), Chief Medical Officer (CMO), and Chief Financial Officer (CFO). The company operates as a publicly traded entity with a global presence, including its headquarters in Germany and operations in the United States.
Top Products and Market Share
Key Offerings
- CVnCoV (COVID-19 Vaccine Candidate): CureVac's mRNA-based COVID-19 vaccine candidate. While it showed efficacy, it did not meet the primary endpoint of non-inferiority to other approved vaccines in its Phase 3 trial. Its market penetration is limited compared to leading competitors. Competitors include Pfizer/BioNTech (Comirnaty), Moderna (Spikevax), and AstraZeneca (Vaxzevria).
- RNActiveu00ae Platform: CureVac's proprietary mRNA technology platform. This is not a product itself but the underlying technology that enables the development of its therapeutic candidates. Its market share is difficult to quantify as it's a technology rather than a sellable product, but it competes with other mRNA platforms developed by companies like Moderna and BioNTech.
- Oncolytic Vaccines (In Development): Pipeline candidates for cancer immunotherapies. These are in various stages of clinical development and do not currently have market share. Competitors in the oncology immunotherapy space are numerous and include companies developing CAR-T therapies, checkpoint inhibitors, and other vaccine approaches.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the vaccine and therapeutic mRNA segment, is dynamic and rapidly evolving. It is characterized by intense research and development, significant investment in novel technologies, and a strong focus on addressing unmet medical needs, especially in infectious diseases and oncology. The COVID-19 pandemic accelerated innovation and investment in mRNA technology.
Positioning
CureVac is positioned as a pioneer and innovator in mRNA technology. Its core strength lies in its proprietary RNActiveu00ae platform, which offers potential advantages in manufacturing, stability, and delivery. However, the company faces strong competition from established players and emerging biotech firms. Its current market share in commercialized products is limited, with its main focus on advancing its pipeline.
Total Addressable Market (TAM)
The TAM for mRNA therapeutics is vast and growing, encompassing infectious disease vaccines, oncology, and rare diseases. Estimates for the global mRNA therapeutics market vary, but projections often place it in the tens to hundreds of billions of dollars in the coming years. CureVac is positioned to capture a portion of this TAM through its diversified pipeline, but its success is contingent on the successful development and commercialization of its drug candidates.
Upturn SWOT Analysis
Strengths
- Pioneering mRNA technology platform (RNActiveu00ae).
- Extensive experience in mRNA manufacturing and development.
- Potential for rapid development of new vaccines and therapies.
- Strong scientific and research foundation.
Weaknesses
- Limited commercialized products and revenue from approved drugs.
- Recent setbacks in clinical trials (e.g., COVID-19 vaccine).
- High reliance on ongoing research and development for future growth.
- Significant competition from well-funded biotech and pharmaceutical companies.
Opportunities
- Expanding the application of mRNA technology to new disease areas (e.g., rare diseases, autoimmune disorders).
- Strategic partnerships and collaborations to advance pipeline candidates.
- Leveraging post-COVID-19 increased interest and investment in mRNA technology.
- Developing next-generation vaccines and therapeutics with improved efficacy and safety profiles.
Threats
- Regulatory hurdles and challenges in clinical trial approvals.
- Intensifying competition and the emergence of superior technologies.
- Pricing pressures and reimbursement challenges for novel therapies.
- Potential for unforeseen adverse events or safety concerns with mRNA technology.
- Funding challenges and dilution risks associated with R&D expenditure.
Competitors and Market Share
Key Competitors
- Moderna Inc. (MRNA)
- BioNTech SE (BNTX)
- Pfizer Inc. (PFE)
Competitive Landscape
CureVac faces intense competition from established players like Pfizer and Moderna, who have successfully commercialized mRNA vaccines. BioNTech, in particular, is a direct competitor through its mRNA platform and COVID-19 vaccine collaboration. CureVac's competitive advantage lies in its proprietary RNActiveu00ae platform and its focus on a broader range of therapeutic areas beyond infectious diseases, especially in oncology. However, its smaller market share and less mature commercial stage compared to some competitors represent a disadvantage.
Growth Trajectory and Initiatives
Historical Growth: Historically, CureVac's growth has been characterized by the expansion of its R&D capabilities, progress in its pipeline development, and the securing of strategic partnerships. Revenue growth has been largely driven by non-dilutive funding sources like collaborations and grants rather than product sales.
Future Projections: Future growth projections for CureVac are heavily dependent on the successful progression of its clinical pipeline, particularly in oncology and infectious diseases. Analyst estimates would focus on potential revenue streams from future product launches and the market potential of its mRNA-based therapies. However, given the inherent risks in drug development, these projections are subject to significant uncertainty.
Recent Initiatives: Recent initiatives have focused on advancing its oncology pipeline, including the development of personalized cancer vaccines and its collaboration with BioNTech for its COVID-19 vaccine. The company has also been exploring strategic partnerships to broaden its reach and accelerate development.
Summary
CureVac NV is a pioneer in mRNA technology with a strong R&D foundation. Its proprietary RNActiveu00ae platform offers significant potential for developing innovative vaccines and therapeutics. However, the company faces considerable challenges, including intense competition from established players, a history of clinical setbacks, and a lack of commercialized products, leading to consistent net losses. Future success hinges on the successful advancement of its pipeline and its ability to navigate the complex regulatory and market landscape.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC filings (10-K, 10-Q)
- Financial news outlets (e.g., Bloomberg, Reuters)
- Biotechnology industry research reports
- Company investor relations website
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. The information is based on publicly available data and estimations, which may be subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CureVac NV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-08-14 | CEO, MD & Member of Management Board Dr. Alexander Zehnder M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 825 | Website https://www.curevac.com |
Full time employees 825 | Website https://www.curevac.com | ||
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics. Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E. coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer. Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.